Proteome Sciences PLC Director/PDMR Shareholding (9693D)
May 03 2017 - 2:01AM
UK Regulatory
TIDMPRM
RNS Number : 9693D
Proteome Sciences PLC
03 May 2017
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Director/PDMR Shareholding
The Company has received notification from Vulpes Life Sciences
Fund ("Vulpes") that on 02 May 2017 it purchased 100,000 ordinary
shares of 1p each in the capital of the Company ("Ordinary Shares")
at a price of 5p per Ordinary Share (the "Purchase"). Following the
Purchase Vulpes has a total direct and indirect interest in
54,143,715 equivalent to 18.38% of Proteome Sciences' total issued
share capital.
The Company would also like to announce that by virtue of Martin
Diggle being a Director of both Vulpes and the Company, he now has
an interest in 54,143,715 Ordinary Shares of the Company
representing 18.38% of the issued share capital of the Company.
1. Details of the person discharging managerial responsibilities / person closely associated
a) Name Vulpes Life Sciences Fund
2. Reason for the Notification
a) Position/status PCA of Martin Diggle (NED)
b) Initial notification/Amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
a) Name Proteome Sciences plc
b) LEI n/a
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
a) Description of the Financial instrument, type of Ordinary Shares of 1p each
instrument
Identification code GB0003104196
b) Nature of the transaction Purchase
c) Price(s) and volume(s) 100,000 Ordinary Shares at 5p per Ordinary Shares
d) Aggregated information:
-- Aggregated volume 100,000 Ordinary Shares of 1p each purchased at a price
-- Price of 5p per Ordinary Share
e) Date of the transaction 2 May 2017
f) Place of the transaction London Stock Exchange, AIM Market (XLON)
For further information:
Proteome Sciences plc
Dr Jeremy Haigh, Chief Executive Officer Tel:
+44 (0)1932 865065
Dr Ian Pike, Chief Scientific Officer
Geoff Ellis, Finance Director
finnCap Limited (Nominated Adviser/Broker)
Geoff Nash/James Thompson Tel: +44 (0)20 7220
0500
Tony Quirke (broking)
IFC Advisory (Financial PR and IR)
Tim Metcalfe/Graham Herring/Miles Nolan Tel: +44 (0)20 3053
8671
Notes for editors:
Proteome Sciences is a leader in applied proteomics offering
high sensitivity, proprietary technologies and workflows for
mapping cell signalling pathways (SysQuant(R) , TMTcalibrator(TM) )
and for the discovery, validation and assay development of protein
biomarkers. The company has its headquarters in Cobham, UK, with
laboratory facilities in Frankfurt, Germany from where the PS
Biomarker Services(TM) division provides outsourced proteomics
services and proprietary biomarker assays to biopharmaceutical and
diagnostics companies and to academia.
Proteome Sciences has patented a number of novel protein
biomarkers for diagnostic and treatment applications in important
areas of human therapeutics such as cancer, stroke and Alzheimer's
disease, and these are available for license.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHSSWFMEFWSEII
(END) Dow Jones Newswires
May 03, 2017 02:01 ET (06:01 GMT)
Proteome Sciences (LSE:PRM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Proteome Sciences (LSE:PRM)
Historical Stock Chart
From Apr 2023 to Apr 2024